Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15470990 | 0.84 | CA2 (0.35) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL22541414 | 0.83 | LMNA (0.42) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL20878313 | 0.81 | LMNA (0.40) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL17123122 | 0.81 | CA2 (0.35) | LMNAKMT2AALDH1A1CA2 | |
| SCHEMBL11851556 | 0.76 | CA2 (0.38) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL435089 | 0.76 | LMNA (0.49) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL31540891 | 0.75 | LMNA (0.43) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL10737745 | 0.74 | PKM (0.50) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL16127631 | 0.74 | LMNA (0.48) | LMNAKMT2APKMNPSR1ALDH1A1 | |
| SCHEMBL18536181 | 0.74 | ALDH1A1 (0.49) | LMNAKMT2APKMNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | ROSKAMP RESEARCH LLC (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | ROSKAMP RESEARCH LLC (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | LMNA 2272/4885KMT2A 4346/4885PKM 1079/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LMNA 170/4885KMT2A 2236/4885PKM 2591/4885 |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | APP, PSEN1, PSEN2 | LMNA 1082/4885KMT2A 4587/4885PKM 1005/4885 |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | LMNA 3437/4885KMT2A 4568/4885PKM 1996/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LMNA 170/4885KMT2A 2236/4885PKM 2591/4885 |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | LMNA 935/4885KMT2A 4711/4885PKM 1665/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | LMNA 2272/4885KMT2A 4346/4885PKM 1079/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | LMNA 935/4885KMT2A 4711/4885PKM 1665/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | LMNA 1651/4885KMT2A 4433/4885PKM 2867/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | LMNA 935/4885KMT2A 4711/4885PKM 1665/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | LMNA 2363/4885KMT2A 3065/4885PKM 1372/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | LMNA 2272/4885KMT2A 4346/4885PKM 1079/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | LMNA 2272/4885KMT2A 4346/4885PKM 1079/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | LMNA 1234/4885KMT2A 4593/4885PKM 3705/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | LMNA 2272/4885KMT2A 4346/4885PKM 1079/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | LMNA 4134/4885KMT2A 4103/4885PKM 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.